Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3B | Q9UBC3 | 6/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11091455 | 0.84 | MEN1 (0.46) | DNMT3BARMAOBKDM4ECYP19A1 | |
| SCHEMBL8875707 | 0.81 | ABCC9 (0.36) | DNMT3BKDM4ECYP3A4 | |
| SCHEMBL5313705 | 0.78 | DNMT3B (0.57) | DNMT3BARMAOBADORA3KDM4E | |
| SCHEMBL3518800 | 0.78 | ALDH1A1 (0.36) | DNMT3BARMAOBADORA3KDM4E | |
| SCHEMBL9056733 | 0.77 | DNMT3B (0.56) | DNMT3BARMAOBADORA3KDM4E | |
| SCHEMBL9056735 | 0.77 | DNMT3B (0.56) | DNMT3BARMAOBADORA3KDM4E | |
| SCHEMBL11091452 | 0.74 | KMT2A (0.46) | DNMT3BARMAOBKDM4ECYP19A1 | |
| SCHEMBL2009148 | 0.73 | MAOB (0.50) | DNMT3BARMAOBADORA3KDM4E | |
| SCHEMBL30300555 | 0.73 | MAOB (0.50) | DNMT3BARMAOBADORA3KDM4E | |
| SCHEMBL29356678 | 0.73 | MAOB (0.50) | DNMT3BARMAOBADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992558-B2 | Controlled release formulation comprising flavoxate | BERLIA, Sushma Paul (IN) | 2024-05-28 | — | — | US | claimed |
| US-20260125352-A1 | PROCESSES FOR CONVERTING FURFURALS | ORIGIN MAT OPERATING INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731615-A2 | PROCESSES FOR CONVERTING FURFURALS | Origin Materials Operating, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024264058-A2 | PROCESSES FOR CONVERTING FURFURALS | ORIGIN MATERIALS OPERATING, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-118265524-A | Controlled release formulation of flavonol methylphenidate and process for preparing the same | 苏什玛·保罗·伯利亚 | 2024-06-28 | — | — | CN | disclosed |
| US-20230330076-A1 | CONTROLLED RELEASE FORMULATIONS OF FLAVOXATE AND PROCESS FOR PREPARATION THEREOF | FLAVOSTAR LLC | 2023-10-19 | — | — | US | disclosed |
| WO-2023089553-A1 | CONTROLLED RELEASE FORMULATIONS OF FLAVOXATE AND PROCESS FOR PREPARATION THEREOF | BERLIA SUSHMA PAUL (IN) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125352-A1 | PROCESSES FOR CONVERTING FURFURALS | JUND, YTHDF1, CMPK1 | DNMT3B 1785/4885AR 4078/4885MAOB 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.